Why two in three cancer deaths still lack an effective screening test

Most global cancer deaths occur in cases where there is no effective screening test. Developing those tests is expensive and, for many diseases, simply not feasible today.

Oncoptic’s platform is designed to radically reduce the cost of discovery and validation of novel diagnostics, opening the door to screening for diseases that previously had none.